Vaxcyte, Inc. (PCVX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Vaxcyte, Inc. (PCVX)
Go deeper and ask any question about PCVX
Company Performance
Current Price
as of Sep 13, 2024$116.00
P/E Ratio
N/A
Market Cap
$14.13B
Description
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Metrics
Overview
- HQSan Carlos, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerPCVX
- Price$116+1.64%
Trading Information
- Market Cap$14.13B
- Float95.77%
- Average Daily Volume (1m)1,412,432
- Average Daily Volume (3m)1,028,832
- EPS-$4.76
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$128.70M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$149.50M
- EV$7.43B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account